Mylan announced it has received final approval for its Abbreviated New Drug Application (ANDA) for Dexmedetomidine HCl Injection, the generic version of Hospira’s Precedex.

Dexmedetomidine HCl, a selective alpha2-adrenergic agonist, is indicated for the sedation of initially intubated and mechanically ventilated patients during treatment in an intensive care setting, and for the sedation of non-intubated patients prior to and/or during surgical and other procedures.

RELATED: Many Anesthesiologists Fail to Wash Hands, Study Finds

Dexmedetomidine HCl Injection is available as a 100mcg/mL strength packaged in 200mcg/2mL single-dose vials. Mylan has launched this product.

For more information call (800) RX-MYLAN or visit Mylan.com.